Molecular testing in lung cancer: The time is now

Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)335-348
Number of pages14
JournalCurrent oncology reports
Volume12
Issue number5
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Keywords

  • Biomarkers
  • EGFR
  • EML4/ALK translocation
  • KRAS
  • Molecular testing
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Molecular testing in lung cancer: The time is now'. Together they form a unique fingerprint.

  • Cite this